ive, easier to use or less expensive or blocked by third party proprietary rights or other means; that the products and product candidates referred to in this report or in our other reports will be successfully commercialized or will enhance our market value; that new product opportunities or commercialization efforts will be successfully established; that third parties on whom we depend will perform as anticipated; that we can raise sufficient capital from partnering, monetization or other fundraising transactions to maintain our stock exchange listing or adequately fund ongoing operations; or that we will not be adversely affected by these or other risks and uncertainties that could impact our operations, business or other matters, as described in more detail in our filings with the Securities and Exchange Commission. We undertake no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof.
Copyright 2012 Cardium Therapeutics, Inc. All rights reserved.
Cardium Therapeutics™, Generx®, Cardionovo™, Tissue Repair™, Gene Activated Matrix™, GAM™, Excellagen™, Excellarate™, Osteorate™, MedPodium™, Appexium™, Linee™, Alena™, Cerex™, D-Sorb™, Neo-Energy®, Neo-Carb Bloc®, Neo-Chill™, and Nutra-Apps® are trademarks of Cardium Therapeutics, Inc. or Tissue Repair Company.
*Note: These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
- Continued - Cardium Therapeutics, Inc.Selected Condensed Consolidated Results of OperationsAs of March 31Page: 1 2 3 4 5 6 7 8 9 10 11 Related biology technology :1
. Cardium to Present at Upcoming Investor Conferences2
. Cardiums Exchange Listing Compliance Plan Accepted by NYSE Amex3
. Cardium Reports Excellagen Matrix Clinical Study Results Accepted for Publication by Peer-Reviewed Journal, and Updates Product Plans4
. Cardium Reports on Third Quarter 2010 Financial Results and Recent Developments5
. Cardium to Present at the LifeTech Capital Miami Medical Investors Conference6
. Cardium Gains Exclusive Access to Novel Polymer-Based Nitric Oxide Technology for Expansion of Wound Healing Product Portfolio7
. Cardium to Present at 10th Annual Biotech in Europe Investor Forum8
. Cardium Regains Listing Compliance With NYSE Amex9
. Cardium to Present at MDB Capital Groups 2010 Bright Lights Conference10
. Cardiums Exchange Listing Compliance Plan Accepted by NYSE AMEX11
. Cardium Reports on Third Quarter 2009 Financial Results and Recent Developments